Match!

Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.

Published on May 14, 2020in Expert Opinion on Biological Therapy3.585
· DOI :10.1080/14712598.2020.1770222
Miguel A. Gonz73
Estimated H-index: 73
(UC: University of Cantabria),
Jose Mayo2
Estimated H-index: 2
+ 2 AuthorsJosé Hernández-Rodríguez33
Estimated H-index: 33
(University of Barcelona)
Abstract
  • References (28)
  • Citations (0)
📖 Papers frequently viewed together
20204.15Immunology
7 Authors (Mingkai Tan, ..., Yaling Shi)
2 Citations
12 Citations
4 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References28
Newest
2 CitationsSource
#1Joshua Geleris (Columbia University)H-Index: 1
#2Yifei Sun (Columbia University)H-Index: 1
Last. R. Graham Barr (Columbia University)H-Index: 69
view all 12 authors...
Abstract Background Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use. Methods We examined the association between hydroxychloroqu...
64 CitationsSource
#1Giulio Cavalli (UniSR: Vita-Salute San Raffaele University)H-Index: 16
#2Giacomo De LucaH-Index: 6
view all 23 authors...
Summary Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of pandemic outbreak, the number of patients can exceed maximum capacity of intensive care units (ICUs), and, thus, these individuals often receive non-invasive ventilation outside of the ICU. Effective treatments for this population are needed urgently. Anakinra is a recombinant interleukin-1 receptor antagonist that might be ...
24 CitationsSource
#1Puja Mehta (UCL: University College London)H-Index: 2
#2Randy Q. Cron (Children's of Alabama)H-Index: 42
Last. Rachel Tattersall (Boston Children's Hospital)H-Index: 5
view all 5 authors...
Summary The term cytokine storm syndromes describes conditions characterised by a life-threatening, fulminant hypercytokinaemia with high mortality. Cytokine storm syndromes can be genetic or a secondary complication of autoimmune or autoinflammatory disorders, infections, and haematological malignancies. These syndromes represent a key area of interface between rheumatology and general medicine. Rheumatologists often lead in management, in view of their experience using intensive immunosuppress...
4 CitationsSource
#1Paola ToniatiH-Index: 4
#1Paola ToniatiH-Index: 1
Last. Eva Andrea BeindorfH-Index: 1
view all 62 authors...
A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleuk...
18 CitationsSource
Antiviral drug remdesivir helps patients hospitalised with covid-19 recover faster and may also reduce mortality, according to the US National Institutes of Health (NIH). The drug—developed by US pharmaceutical company Gilead—is being tested through a randomised, controlled trial involving 1063 patients from several countries including the US, UK, and Singapore. The study began in February. Currently, no official results have been published, however the NIH said that the independent data and saf...
4 CitationsSource
#1Xiaoling Xu (USTC: University of Science and Technology of China)H-Index: 4
#2Mingfeng HanH-Index: 1
Last. Xiuyong LiH-Index: 1
view all 13 authors...
After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or...
170 CitationsSource
#1Pedram Ahmadpoor (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 10
Last. Lionel RostaingH-Index: 69
view all 2 authors...
Abstract The Covid-19 pandemic has already affected many thousands of people and has become the greatest health challenge worldwide [1]. The range of clinical presentations varies from asymptomatic and mild clinical symptoms to acute respiratory-distress syndrome (ARDS) and death. Due to the unknown number of asymptomatic viral-shedding and pauci-symptomatic people in the community, the total number of infections is uncertain. As yet, effective treatment is unavailable. However, the results of p...
11 CitationsSource
#1Chien-Yu Cheng (NYMU: National Yang-Ming University)H-Index: 8
#2Yu-Lin LeeH-Index: 3
Last. Shu-Hsing Cheng (TMU: Taipei Medical University)H-Index: 5
view all 7 authors...
Abstract An increase of Ct values was 0.9 per day in 2 cases of COVID-19 treated with lopinavir/ritonavir (LPV/r), an increase was 1.0 per day in 3 cases without LPV/r through illness day 1 to 10, indicating that LPV/r did not shorten the duration of SARS CoV-2 shedding.
7 CitationsSource
#1Bin Cao (China-Japan Friendship Hospital)H-Index: 1
#2Yeming Wang (China-Japan Friendship Hospital)H-Index: 1
Last. Ming Wei (China-Japan Friendship Hospital)H-Index: 1
view all 65 authors...
Abstract Background No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open-label trial involvin...
550 CitationsSource
Cited By0
Newest